Previous 10 | Next 10 |
PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA submission for PNT2001 program in H1 2023 INDIANAPOLIS, Oct. 17, 2022 (GLOBE NEWSW...
INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the closing of its pr...
Truist has initiated POINT Biopharma Global as a buy citing the potential of PNT2002, its prostate cancer therapy candidate in phase 3. The firm has a $22 price target (~161% upside based on Thursday's close). Analyst Nicole Germino said that PNT2002 is de-risked based on key ...
Investors were not kind to Point Biopharma Global (NASDAQ: PNT) on Wednesday. The specialty biotech saw its share price crumble by more than 12% on the day, in sharp contrast to the marginal gain of the S&P 500 index. The major culprit was a new financing move announced by t...
POINT Biopharma Global ( NASDAQ: PNT ) shares dropped 9.6% after-hours on Tuesday after pricing its public offering of 13.9M shares of common stock at a public offering price of $9.00/share for expected gross proceeds to be ~$125M. Underwriters are granted a 30-da...
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced the pricing of its pu...
POINT Biopharma Global ( NASDAQ: PNT ) has announced that it has commenced an underwritten public offering of its common stock. In addition, underwriters were granted a 30-day option to purchase up to an additional 15% of its common stock being sold in the offering at the ...
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, today announced that it has commenced...
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR) was achieved in 60% of the 10 participants with evaluable disease at baselin...
Radiopharmaceutical company Point Biopharma Global Inc. ( NASDAQ: PNT ) dropped ~28% after the biotech announced the publication of an abstract containing initial data from a Phase 3 trial for its radioligand agent PNT2002. The data from the lead-in cohort of the multi-c...
News, Short Squeeze, Breakout and More Instantly...
POINT Biopharma Global Inc. Company Name:
PNT Stock Symbol:
NASDAQ Market:
POINT Biopharma Global Inc. Website:
NORTHAMPTON, MA / ACCESSWIRE / June 25, 2024 / Pentair Greg Claffey, Group President, Pentair Pool (right) presents Pentair Pool Step Into Swim sponsorship check to Rowdy Gaines, Vice President Partnerships and Development, PHTA, and Olympic Gold Medalist. As published on the Pentair Blog . ...
LONDON, UK / ACCESSWIRE / April 18, 2024 / Pentair plc (NYSE:PNR), a leader in helping the world sustainably move, improve and enjoy water, life's most essential resource, today released its 2023 Corporate Responsibility Report, reporting on the Company's efforts and progress toward Making Bett...
Lilly Completes Acquisition of POINT Biopharma PR Newswire INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceuti...